Peng Zhaohui, president of Shenzhen Sibiono Genetech Co Ltd, is accustomed to explaining basic data from his Gendicine  the world's first commercialized gene therapy to foreign scientists.

"Although much of our research and clinical data has been published domestically, most of it is inaccessible to foreign researchers," said Peng.
 
As a result, the significant scientific breakthrough has been greeted with indifference or suspicion by many foreign researchers, according to a recent article in the UK-based journal Nature Reviews Drug Discovery.

(For more biz stories, please visit Industry Updates)